Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus.
Calcineurin mutation or inhibition enhanced the antifungal morphological effect of cell wall inhibitors caspofungin or nikkomycin Z against Aspergillus fumigatus. Quantification of 1,3-beta-d-glucan revealed decreased amounts in the calcineurin A (DeltacnaA) mutant. Calcineurin can be an excellent adjunct therapeutic target in combination with other cell wall inhibitors against A. fumigatus.
Steinbach
William J
WJ
Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA. stein022@mc.duke.edu
Cramer
Robert A
RA
Perfect
B Zachary
BZ
Henn
Christina
C
Nielsen
Kirsten
K
Heitman
Joseph
J
Perfect
John R
JR
D000617:Aminoglycosides / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000254:growth & development; D019703:Calcineurin / Q000235:genetics; D065095:Calcineurin Inhibitors; D000077336:Caspofungin; D002473:Cell Wall / Q000187:drug effects*; D004357:Drug Synergism; D054714:Echinocandins; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015966:Gene Expression Regulation, Fungal; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D009154:Mutation; D010456:Peptides, Cyclic / Q000494:pharmacology; D016559:Tacrolimus / Q000494:pharmacology
D000617:Aminoglycosides; D000935:Antifungal Agents; D065095:Calcineurin Inhibitors; D054714:Echinocandins; D004791:Enzyme Inhibitors; D055666:Lipopeptides; D010456:Peptides, Cyclic; C011952:nikkomycin; D019703:Calcineurin; D000077336:Caspofungin; D016559:Tacrolimus